This company has been marked as potentially delisted and may not be actively trading.

GX Acquisition (GXGX) Competitors

GXGX vs. WHWK, CNTN, MENS, ANTX, and TTRX

Should you be buying GX Acquisition stock or one of its competitors? The main competitors of GX Acquisition include Whitehawk Therapeutics (WHWK), Hillstream Biopharma (CNTN), Jyong Biotech (MENS), Anthem (ANTX), and Turn Therapeutics (TTRX).

How does GX Acquisition compare to Whitehawk Therapeutics?

GX Acquisition (NASDAQ:GXGX) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

: Whitehawk Therapeutics' return on equity of -62.88% beat GX Acquisition's return on equity.
Company Net Margins Return on Equity Return on Assets
GX Acquisition N/A -985.20% -6.02%
Whitehawk Therapeutics N/A -62.88% -58.98%
: Whitehawk Therapeutics has higher revenue and earnings than GX Acquisition.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GX Acquisition N/A N/A -$49.26M N/A N/A
Whitehawk Therapeutics $7.14M 28.94 -$20.60M $0.47 8.89
: Whitehawk Therapeutics has a consensus price target of $7.00, indicating a potential upside of 67.46%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Whitehawk Therapeutics is more favorable than GX Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GX Acquisition
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Whitehawk Therapeutics
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.50
: In the previous week, Whitehawk Therapeutics had 2 more articles in the media than GX Acquisition. MarketBeat recorded 2 mentions for Whitehawk Therapeutics and 0 mentions for GX Acquisition. Whitehawk Therapeutics' average media sentiment score of 1.16 beat GX Acquisition's score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
GX Acquisition Neutral
Whitehawk Therapeutics Positive
: GX Acquisition has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.
: 61.7% of GX Acquisition shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
GX Acquisition	N/A	-985.20%	-6.02%
Whitehawk Therapeutics	N/A	-62.88%	-58.98%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GX Acquisition	N/A	N/A	-$49.26M	N/A	N/A
Whitehawk Therapeutics	$7.14M	28.94	-$20.60M	$0.47	8.89

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GX Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Overall Sentiment
GX Acquisition	Neutral
Whitehawk Therapeutics	Positive

Summary

Whitehawk Therapeutics beats GX Acquisition on 10 of the 12 factors compared between the two stocks.

How does GX Acquisition compare to Hillstream Biopharma?

GX Acquisition (NASDAQ:GXGX) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

: 61.7% of GX Acquisition shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 6.7% of Hillstream Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Hillstream Biopharma's return on equity of -35.59% beat GX Acquisition's return on equity.
Company Net Margins Return on Equity Return on Assets
GX Acquisition N/A -985.20% -6.02%
Hillstream Biopharma N/A -35.59% -27.05%
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GX Acquisition N/A N/A -$49.26M N/A N/A
Hillstream Biopharma N/A N/A -$35.92M -$3.99 N/A
: GX Acquisition has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, Hillstream Biopharma has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500.
: In the previous week, GX Acquisition's average media sentiment score of 0.00 equaled Hillstream Biopharma'saverage media sentiment score.
Company Overall Sentiment
GX Acquisition Neutral
Hillstream Biopharma Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GX Acquisition
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Hillstream Biopharma
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00

Company	Net Margins	Return on Equity	Return on Assets
GX Acquisition	N/A	-985.20%	-6.02%
Hillstream Biopharma	N/A	-35.59%	-27.05%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GX Acquisition	N/A	N/A	-$49.26M	N/A	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$3.99	N/A

Company	Overall Sentiment
GX Acquisition	Neutral
Hillstream Biopharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GX Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Hillstream Biopharma beats GX Acquisition on 5 of the 7 factors compared between the two stocks.

How does GX Acquisition compare to Jyong Biotech?

GX Acquisition (NASDAQ:GXGX) and Jyong Biotech (NASDAQ:MENS) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

: Jyong Biotech's return on equity of 0.00% beat GX Acquisition's return on equity.
Company Net Margins Return on Equity Return on Assets
GX Acquisition N/A -985.20% -6.02%
Jyong Biotech N/A N/A N/A
: In the previous week, Jyong Biotech had 2 more articles in the media than GX Acquisition. MarketBeat recorded 2 mentions for Jyong Biotech and 0 mentions for GX Acquisition. GX Acquisition's average media sentiment score of 0.00 equaled Jyong Biotech'saverage media sentiment score.
Company Overall Sentiment
GX Acquisition Neutral
Jyong Biotech Neutral
: 61.7% of GX Acquisition shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GX Acquisition
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Jyong Biotech
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GX Acquisition N/A N/A -$49.26M N/A N/A
Jyong Biotech N/A N/A N/A N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
GX Acquisition	N/A	-985.20%	-6.02%
Jyong Biotech	N/A	N/A	N/A

Company	Overall Sentiment
GX Acquisition	Neutral
Jyong Biotech	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GX Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GX Acquisition	N/A	N/A	-$49.26M	N/A	N/A
Jyong Biotech	N/A	N/A	N/A	N/A	N/A

Summary

Jyong Biotech beats GX Acquisition on 4 of the 5 factors compared between the two stocks.

How does GX Acquisition compare to Anthem?

GX Acquisition (NASDAQ:GXGX) and Anthem (NASDAQ:ANTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GX Acquisition
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Anthem
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Anthem's return on equity of -55.04% beat GX Acquisition's return on equity.
Company Net Margins Return on Equity Return on Assets
GX Acquisition N/A -985.20% -6.02%
Anthem N/A -55.04% -49.13%
: In the previous week, Anthem had 6 more articles in the media than GX Acquisition. MarketBeat recorded 6 mentions for Anthem and 0 mentions for GX Acquisition. GX Acquisition's average media sentiment score of 0.00 equaled Anthem'saverage media sentiment score.
Company Overall Sentiment
GX Acquisition Neutral
Anthem Neutral
: 61.7% of GX Acquisition shares are owned by institutional investors. Comparatively, 90.5% of Anthem shares are owned by institutional investors. 20.8% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GX Acquisition N/A N/A -$49.26M N/A N/A
Anthem N/A N/A -$35.17M -$1.16 N/A
: GX Acquisition has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, Anthem has a beta of -0.95, meaning that its share price is 195% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GX Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
GX Acquisition	N/A	-985.20%	-6.02%
Anthem	N/A	-55.04%	-49.13%

Company	Overall Sentiment
GX Acquisition	Neutral
Anthem	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GX Acquisition	N/A	N/A	-$49.26M	N/A	N/A
Anthem	N/A	N/A	-$35.17M	-$1.16	N/A

Summary

Anthem beats GX Acquisition on 6 of the 8 factors compared between the two stocks.

How does GX Acquisition compare to Turn Therapeutics?

GX Acquisition (NASDAQ:GXGX) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

: 61.7% of GX Acquisition shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: Turn Therapeutics has a consensus price target of $8.00, indicating a potential upside of 115.34%. Given Turn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Turn Therapeutics is more favorable than GX Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GX Acquisition
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Turn Therapeutics
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Turn Therapeutics' return on equity of 0.00% beat GX Acquisition's return on equity.
Company Net Margins Return on Equity Return on Assets
GX Acquisition N/A -985.20% -6.02%
Turn Therapeutics N/A N/A N/A
: In the previous week, GX Acquisition's average media sentiment score of 0.00 equaled Turn Therapeutics'average media sentiment score.
Company Overall Sentiment
GX Acquisition Neutral
Turn Therapeutics Neutral
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GX Acquisition N/A N/A -$49.26M N/A N/A
Turn Therapeutics N/A N/A -$3.19M -$0.16 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GX Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
GX Acquisition	N/A	-985.20%	-6.02%
Turn Therapeutics	N/A	N/A	N/A

Company	Overall Sentiment
GX Acquisition	Neutral
Turn Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GX Acquisition	N/A	N/A	-$49.26M	N/A	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.16	N/A

Summary

Turn Therapeutics beats GX Acquisition on 6 of the 7 factors compared between the two stocks.

Get GX Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GXGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GXGX vs. The Competition

Export

Metric	GX Acquisition	Pharmaceutical Preparations Industry	Medical Sector	NASDAQ Exchange
Market Cap	$49.23M	$886.50M	$6.24B	$11.87B
Dividend Yield	N/A	4.84%	2.73%	5.21%
P/E Ratio	N/A	1.71	29.06	28.45
Price / Sales	N/A	119.94	475.43	61.47
Price / Cash	N/A	20.07	27.62	36.52
Price / Book	9.79	7.59	9.69	6.64
Net Income	-$49.26M	-$4.80M	$3.55B	$332.53M

GX Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GXGX GX Acquisition	N/A	$1.37 -1.4%	N/A	N/A	$49.23M	N/A	N/A	N/A	Gap Up
WHWK Whitehawk Therapeutics	4.1862 of 5 stars	$4.03 -3.4%	$7.00 +73.7%	N/A	$196.81M	$7.15M	8.57	21
CNTN Hillstream Biopharma	0.0754 of 5 stars	$3.41 +1.2%	N/A	N/A	$190.93M	N/A	N/A	2
MENS Jyong Biotech	N/A	$2.19 -3.5%	N/A	N/A	$166.50M	N/A	N/A	31
ANTX Anthem	0.1858 of 5 stars	$4.34 +1.4%	$2.00 -53.9%	N/A	$154.06M	N/A	N/A	N/A	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GXGX) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GX Acquisition (GXGX) Competitors

GXGX vs. WHWK, CNTN, MENS, ANTX, and TTRX

How does GX Acquisition compare to Whitehawk Therapeutics?

Summary

How does GX Acquisition compare to Hillstream Biopharma?

Summary

How does GX Acquisition compare to Jyong Biotech?

Summary

How does GX Acquisition compare to Anthem?

Summary

How does GX Acquisition compare to Turn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GXGX vs. The Competition

GX Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GX Acquisition (GXGX) Competitors

GXGX vs. WHWK, CNTN, MENS, ANTX, and TTRX

How does GX Acquisition compare to Whitehawk Therapeutics?

Summary

How does GX Acquisition compare to Hillstream Biopharma?

Summary

How does GX Acquisition compare to Jyong Biotech?

Summary

How does GX Acquisition compare to Anthem?

Summary

How does GX Acquisition compare to Turn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GXGX vs. The Competition

GX Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools